TNFRSF25 and type 2 diabetes mellitus: The latest research shows that IL-33 can induce fat retention and the expression of DR3 in human peripheral blood ILC2s and participate in canonical and/or noncanonical NF-κB pathways to improve glucose tolerance and regulate the metabolic homeostasis of adipose tissue; thus, IL-33 can be used to treat patients with type 2 diabetes (T2DM) (78).